- Home
- RDZN vs YARW Comparison
RDZN vs YARW Comparison
Compare RDZN & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDZN | YARW |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.8M | 114.6M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RDZN | YARW |
|---|---|---|
| Price | $1.38 | $25.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 351.0K | 136.5K |
| Earning Date | 02-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.12 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $55,021,792.00 | N/A |
| Revenue This Year | $33.77 | N/A |
| Revenue Next Year | $51.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.21 | N/A |
| 52 Week Low | $0.86 | $23.68 |
| 52 Week High | $2.56 | $44.28 |
Technical Indicators
Market Signals| Indicator | RDZN | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 55.75 | 34.18 |
| Support Level | $1.05 | $24.00 |
| Resistance Level | $1.47 | $32.89 |
| Average True Range (ATR) | 0.09 | 2.45 |
| MACD | 0.02 | -0.13 |
| Stochastic Oscillator | 88.55 | 8.01 |
Price Performance
Historical ComparisonAbout RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express. Geographically, the company operates in India, United States of America, United Kingdom, and China. It generates maximum revenue form India.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.